At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 297 enrolled
Drug / intervention
GSK3326595 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
In Brief
A Phase 1 clinical trial evaluating GSK3326595 and Pembrolizumab for Neoplasms. Completed, enrolled 297 participants across 15 sites in 4 countries.
Detailed Summary
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and non-Hodgkin's lymphoma (NHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesCanada, France, Netherlands, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartAug 2016
Primary CompletionAug 2023
TodayJul 2026
First PostedMay 26, 2016
Enrollment StartAug 30, 2016
Primary CompletionAug 30, 2023
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 10.1 years ago
Interventions
GSK3326595drug
GSK3326595 will be administered with and without food, in tablet and capsule formulation.
Pembrolizumabdrug
Pembrolizumab will be administered.